Maryam Momeni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maryam Momeni has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alieh Gholaminejad
Isfahan University of Medical Sciences
2 shared publications - Amir Roointan
Isfahan University of Medical Sciences
1 shared publication - Arian Veyssi
The University of Texas at Austin
1 shared publication - Maryam Siahtiri
Department of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Iran, Iran
1 shared publication Mohammadjavad Naghdibadi
1 shared publication- Nikita Krishnan
Center for Paralysis Research, Purdue University, West Lafayette, IN, 47907, USA
1 shared publication
Latest Publications
- Open Access
- 15 October 2025
- Published by MDPI AG in Preprints.org
From Tumor Pathways to Blood Signature: A Machine Learning-Validated 5-miRNA Signature for the Early Detection of Gastric Cancer
Background: Gastric cancer (GC) remains a leading cause of global cancer mortality, with late-stage diagnosis contributing significantly to poor patient outcomes. Circulating microRNAs (miRNAs) offer promise due to their stability in biofluids and established roles in carcinogenesis. However, existing miRNA biomarker candidates for GC suffer from inconsistent validation across studies, limited specificity, and insufficient mechanistic links to gastric tumor biology. We addressed this by integrating tissue and blood transcriptomics to identify GC-specific miRNAs, which were then validated using machine learning. Methods: Dysregulated genes (DEGs) and miRNAs (DEMs) were identified from tissue mRNA (GSE54129, GSE113255) and blood miRNA/mRNA datasets (GSE106817, GSE174302). Pathway enrichment (Reactome) revealed GC-specific pathways shared between tissue DEGs and blood DEM targets. Targets of 59 DEMs were enriched in these pathways in the blood miRNA dataset. From these, a 5-miRNA panel was selected using 10 machine learning feature selection methods (e.g., Gini Index, Information Gain) and validated using Random Forest and Naïve Bayes classifiers on discovery (GSE106817) and external (GSE164174) datasets. Results: Integration identified 59 GC-specific extracellular miRNAs linked to 39 enriched pathways (e.g., signaling, metabolism). The 5-miRNA panel (hsa-miR-124-3p, hsa-miR-23a-3p, hsa-miR-22-3p, hsa-miR-29b-3p, hsa-miR-92a-3p) achieved near-perfect discovery performance (RF: AUC=98.50%, ACC=98.36%) and high external validation (AUC=95.30%, ACC=89.24%). Conclusion: Our pipeline bridges tissue pathology and circulating miRNA profiles, yielding a highly specific 5-miRNA Blood Signature with clinical diagnostic potential for GC.
- 15 October 2025
- Published by MDPI AG in Preprints.org
Open AccessFrom Tumor Pathways to Blood Signature: A Machine Learning-Validated 5-miRNA Signature for the Early Detection of Gastric Cancer
Background: Gastric cancer (GC) remains a leading cause of global cancer mortality, with late-stage diagnosis contributing significantly to poor patient outcomes. Circulating microRNAs (miRNAs) offer promise due to their stability in biofluids and established roles in carcinogenesis. However, existing miRNA biomarker candidates for GC suffer from inconsistent validation across studies, limited specificity, and insufficient mechanistic links to gastric tumor biology. We addressed this by integrating tissue and blood transcriptomics to identify GC-specific miRNAs, which were then validated using machine learning. Methods: Dysregulated genes (DEGs) and miRNAs (DEMs) were identified from tissue mRNA (GSE54129, GSE113255) and blood miRNA/mRNA datasets (GSE106817, GSE174302). Pathway enrichment (Reactome) revealed GC-specific pathways shared between tissue DEGs and blood DEM targets. Targets of 59 DEMs were enriched in these pathways in the blood miRNA dataset. From these, a 5-miRNA panel was selected using 10 machine learning feature selection methods (e.g., Gini Index, Information Gain) and validated using Random Forest and Naïve Bayes classifiers on discovery (GSE106817) and external (GSE164174) datasets. Results: Integration identified 59 GC-specific extracellular miRNAs linked to 39 enriched pathways (e.g., signaling, metabolism). The 5-miRNA panel (hsa-miR-124-3p, hsa-miR-23a-3p, hsa-miR-22-3p, hsa-miR-29b-3p, hsa-miR-92a-3p) achieved near-perfect discovery performance (RF: AUC=98.50%, ACC=98.36%) and high external validation (AUC=95.30%, ACC=89.24%). Conclusion: Our pipeline bridges tissue pathology and circulating miRNA profiles, yielding a highly specific 5-miRNA Blood Signature with clinical diagnostic potential for GC.
- Open Access
- 28 February 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 135-150
Clear Cell Renal Cell Carcinoma: A Comprehensive in silico Study in Searching for Therapeutic Targets
Introduction: Clear cell renal cell carcinoma (ccRCC) is recognized as one of the leading causes of illness and death worldwide. Understanding the molecular mechanisms in ccRCC pathogenesis is crucial for discovering novel therapeutic targets and developing efficient drugs. With the application of a comprehensive in silico analysis of the ccRCC-related array sets, the main objective of this study was to discover the top molecules and pathways in the pathogenesis of this cancer. Methods: ccRCC microarray datasets were downloaded from the Gene Expression Omnibus database, and after quality checking, normalization, and analysis using the Limma algorithm, differentially expressed genes (DEGs) were identified, considering the adjusted p value Results: Three datasets, including GSE11151, GSE12606, and GSE36897, were retrieved, merged, normalized, and analyzed. Using WGCNA, the DEGs were clustered into eight different modules. Translocation of ZAP-70 to immunological synapse, endosomal/vacuolar pathway, cell surface interactions at the vascular wall, and immune-related pathways were the topmost enriched terms for the ccRCC-correlated DEGs. Twelve genes including PTPRC, ITGAM, TLR2, CD86, PLEK, TYROBP, ITGB2, RAC2, CSF1R, CCR5, CCL5, and LCP2 were introduced as hub genes. All the 12 hub genes were upregulated in ccRCC samples and showed a positive correlation with the infiltration of different immune cells. According to the DGIdb database, 127 drugs, including tyrosine kinase inhibitors, glucocorticoids, and chemotaxis targeting molecules, were identified to interact with the hub genes. Conclusion: By utilizing an integrative bioinformatics approach, this experiment shed light on the underlying pathways in the pathogenesis of ccRCC and introduced several potential therapeutic targets for repurposing or developing novel drugs for an efficient treatment of this cancer. Our next step would be to assess the gene expression profiles of the identified hubs in different cell populations in the tumor microenvironment.
- 28 February 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 135-150
Open AccessClear Cell Renal Cell Carcinoma: A Comprehensive in silico Study in Searching for Therapeutic Targets
Introduction: Clear cell renal cell carcinoma (ccRCC) is recognized as one of the leading causes of illness and death worldwide. Understanding the molecular mechanisms in ccRCC pathogenesis is crucial for discovering novel therapeutic targets and developing efficient drugs. With the application of a comprehensive in silico analysis of the ccRCC-related array sets, the main objective of this study was to discover the top molecules and pathways in the pathogenesis of this cancer. Methods: ccRCC microarray datasets were downloaded from the Gene Expression Omnibus database, and after quality checking, normalization, and analysis using the Limma algorithm, differentially expressed genes (DEGs) were identified, considering the adjusted p value Results: Three datasets, including GSE11151, GSE12606, and GSE36897, were retrieved, merged, normalized, and analyzed. Using WGCNA, the DEGs were clustered into eight different modules. Translocation of ZAP-70 to immunological synapse, endosomal/vacuolar pathway, cell surface interactions at the vascular wall, and immune-related pathways were the topmost enriched terms for the ccRCC-correlated DEGs. Twelve genes including PTPRC, ITGAM, TLR2, CD86, PLEK, TYROBP, ITGB2, RAC2, CSF1R, CCR5, CCL5, and LCP2 were introduced as hub genes. All the 12 hub genes were upregulated in ccRCC samples and showed a positive correlation with the infiltration of different immune cells. According to the DGIdb database, 127 drugs, including tyrosine kinase inhibitors, glucocorticoids, and chemotaxis targeting molecules, were identified to interact with the hub genes. Conclusion: By utilizing an integrative bioinformatics approach, this experiment shed light on the underlying pathways in the pathogenesis of ccRCC and introduced several potential therapeutic targets for repurposing or developing novel drugs for an efficient treatment of this cancer. Our next step would be to assess the gene expression profiles of the identified hubs in different cell populations in the tumor microenvironment.
- Open Access
sMAP: An interactive microarray data analysis tool for early-stage researchers
Microarray data enables biologists to extract differentially expressed genes (DEGs) across multiple phenotypes. While several pipelines and tools exist to perform microarray data analysis, they are targeted to users with moderate to advanced computational understanding and lack an easy-to-use, interactive and dynamic methodology to perform analysis assisted with comprehensive learning resources. In this study, we developed an interactive application “sMAP” (Standard Microarray Analysis Pipeline) to make transcriptome microarray data analysis more accessible in learning environments and to enable the identification of significant pathological biomarkers. In a case study of colorectal cancer, we showed that sMAP enabled us to reproduce previous findings and discover relevant pathways. sMAP provides a comprehensive set of tutorials and learning documentation to help early-stage researchers. The latest URLs of sMAP’s hosting, tutorial, and frequently updated documentation can be found at https://github.com/BI-STEM-Away/sMAP .
Open AccesssMAP: An interactive microarray data analysis tool for early-stage researchers
Microarray data enables biologists to extract differentially expressed genes (DEGs) across multiple phenotypes. While several pipelines and tools exist to perform microarray data analysis, they are targeted to users with moderate to advanced computational understanding and lack an easy-to-use, interactive and dynamic methodology to perform analysis assisted with comprehensive learning resources. In this study, we developed an interactive application “sMAP” (Standard Microarray Analysis Pipeline) to make transcriptome microarray data analysis more accessible in learning environments and to enable the identification of significant pathological biomarkers. In a case study of colorectal cancer, we showed that sMAP enabled us to reproduce previous findings and discover relevant pathways. sMAP provides a comprehensive set of tutorials and learning documentation to help early-stage researchers. The latest URLs of sMAP’s hosting, tutorial, and frequently updated documentation can be found at https://github.com/BI-STEM-Away/sMAP .